McNulty Bio (CEO Jeon Hyeon-su), a subsidiary of total healthcare specialist Korea McNulty (CEO Lee Eun-jung), announced on the 18th that it has signed a strategic business agreement (MOU) with MD Healthcare for joint development and distribution of health functional foods.
Through this agreement, the two companies announced their goal: to combine their respective core competencies to jointly develop and market differentiated functional products. Specifically, MD Healthcare's next-generation functional ingredient development capabilities and McNulty Bio's distribution and marketing expertise are expected to accelerate the development of high-performance health functional foods.
McNulty Bio, a subsidiary of Korea McNulty, is a bio-healthcare company specializing in the discovery and distribution of scientifically evidence-based functional foods. Their proprietary black cumin extract powder, developed using proprietary technology, has been recognized as an individually approved raw material by the Ministry of Food and Drug Safety, and they are expanding their product lineup centered around this raw material.
MD Healthcare is developing next-generation biomaterials with antioxidant, anti-inflammatory, immunomodulatory, and metabolic benefits, utilizing extracellular vesicles secreted by probiotics, commensal microorganisms found in the gut. Beyond simple raw material discovery, MD Healthcare is expanding its global market competitiveness by leveraging its integrated capabilities, encompassing basic science research, functional verification, safety assurance, and production quality management.
McNulty Bio CEO Jeon Hyeon-su said, “While the obesity treatment market has recently been expanding, existing GLP-1 series injections have side effects and cost burdens, and body fat reduction foods on the market are focused on reducing fat,” and “Black cumin, which we developed, is a functional food that enables not only safe weight management but also comprehensive health management, so we believe that this agreement will accelerate its commercialization.”
MD Healthcare CEO Kim Yoon-geun said, “Through this partnership between our two companies, we expect to create a powerful synergy that will allow us to quickly commercialize scientifically reliable functional raw materials and stably supply them to the market based on the technological prowess, distribution networks, and planning capabilities of both companies.”
You must be logged in to post a comment.